Skip to main content

Acorn Capital Advisors, LLC

13F filer · CIK 0002054410
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$366MU.S. long equity reported on 13F
Positions201 new · 3 closed
Net flow last quarter-$75.6MBuys minus sells
Top 10 positions weight90.2%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202620 positions
CGONCG Oncology, Inc.$80.4M21.94%1.28%+0.1%Q4 2024
URGNUroGen Pharma Ltd.$61.6M16.80%3.42%Not reportedQ4 2024
TRVITrevi Therapeutics, Inc.$40M10.92%1.51%Not reportedQ4 2024
CADLCandel Therapeutics, Inc.$36M9.83%4.60%Not reportedQ4 2024
PBYIPuma Biotechnology, Inc.$33.5M9.14%8.08%Not reportedQ4 2024
JBIOJade Biosciences, Inc.$21.9M5.98%1.55%+25.4%Q1 2026
BCAXBicara Therapeutics Inc.$19.1M5.21%0.98%0.0%Q4 2024
KPTIKaryopharm Therapeutics Inc.$14.8M4.05%6.69%+427.4%Q1 2026
OKUROnKure Therapeutics, Inc.$12.9M3.53%7.03%Not reportedQ4 2024
HELPCybin Inc.$10.2M2.78%2.98%Not reportedQ4 2024
TARAProtara Therapeutics, Inc.$6.69M1.83%2.97%Not reportedQ4 2024
AURAAura Biosciences, Inc.$6.6M1.80%0.90%+56.0%Q1 2025
LONALeonaBio, Inc.$5.83M1.59%6.73%Not reportedQ4 2025
VSTMVerastem, Inc.$5.61M1.53%1.62%Not reportedQ4 2024
WHWKWhitehawk Therapeutics, Inc.$5.22M1.42%2.00%Not reportedQ4 2024
QTTBQ32 Bio Inc.$2.75M0.75%0.91%-31.4%Q4 2024
ENGNenGene Therapeutics Inc.$2.2M0.60%1.90%NewQ2 2026
JSPRJasper Therapeutics, Inc.$604K0.16%5.12%+1.9%Q3 2025
BCABBioAtla, Inc.$448K0.12%6.50%0.0%Q4 2024
VYNEYarrow Bioscience, Inc.$9260.00%Not reportedNot reportedQ4 2024
Q1 2026Reported May 15, 202622 positions
TERNTerns Pharmaceuticals, Inc.$92.1M26.17%1.51%Not reportedQ4 2024
CGONCG Oncology, Inc.$76.6M21.77%1.28%-0.1%Q4 2024
URGNUroGen Pharma Ltd.$30.1M8.55%3.44%+15.5%Q4 2024
PBYIPuma Biotechnology, Inc.$26.4M7.50%8.12%Not reportedQ4 2024
TRVITrevi Therapeutics, Inc.$25.6M7.27%1.67%Not reportedQ4 2024
CADLCandel Therapeutics, Inc.$17.2M4.89%4.77%+35.6%Q4 2024
BCAXBicara Therapeutics Inc.$12.8M3.64%0.98%Not reportedQ4 2024
OKUROnKure Therapeutics, Inc.$11.8M3.34%20.77%Not reportedQ4 2024
JBIOJade Biosciences, Inc.$11.1M3.14%1.59%NewQ1 2026
TARAProtara Therapeutics, Inc.$9.13M2.59%3.18%Not reportedQ4 2024
VSTMVerastem, Inc.$7.79M2.21%1.67%Not reportedQ4 2024
HELPCybin Inc.$7.39M2.10%2.98%-2.1%Q4 2024
LONALeonaBio, Inc.$6.52M1.85%6.76%+26.5%Q4 2025
AURAAura Biosciences, Inc.$3.99M1.13%0.93%Not reportedQ1 2025
WHWKWhitehawk Therapeutics, Inc.$3.93M1.12%2.41%Not reportedQ4 2024
CRDFCardiff Oncology, Inc.$2.85M0.81%2.58%-10.2%Q4 2024
QTTBQ32 Bio Inc.$2.02M0.57%2.15%-36.2%Q4 2024
KPTIKaryopharm Therapeutics Inc.$1.6M0.46%1.28%NewQ1 2026
JSPRJasper Therapeutics, Inc.$1.24M0.35%5.04%-21.0%Q3 2025
XFORX4 Pharmaceuticals, Inc$967K0.27%0.25%-14.4%Q4 2024
BCABBioAtla, Inc.$865K0.25%325.76%+11.8%Q4 2024
VYNEYarrow Bioscience, Inc.$8550.00%Not reportedNot reportedQ4 2024
Q4 2025Reported Feb 17, 202621 positions
TERNTerns Pharmaceuticals, Inc.$70.5M23.90%1.55%-11.4%Q4 2024
CGONCG Oncology, Inc.$47M15.92%1.40%Not reportedQ4 2024
URGNUroGen Pharma Ltd.$33.9M11.49%3.00%+15.0%Q4 2024
TRVITrevi Therapeutics, Inc.$26.9M9.10%1.67%Not reportedQ4 2024
PBYIPuma Biotechnology, Inc.$24.6M8.33%8.20%Not reportedQ4 2024
CADLCandel Therapeutics, Inc.$14.6M4.94%4.70%Not reportedQ4 2024
HELPCybin Inc.$12.9M4.36%7.28%+114.2%Q4 2024
VSTMVerastem, Inc.$11.3M3.84%1.89%+88.5%Q4 2024
BCAXBicara Therapeutics Inc.$10.8M3.67%1.14%Not reportedQ4 2024
TARAProtara Therapeutics, Inc.$9.34M3.16%3.27%Not reportedQ4 2024
OKUROnKure Therapeutics, Inc.$8.24M2.79%849.31%Not reportedQ4 2024
CRDFCardiff Oncology, Inc.$5.51M1.87%2.87%Not reportedQ4 2024
LONALeonaBio, Inc.$3.8M1.29%5.37%NewQ4 2025
JSPRJasper Therapeutics, Inc.$3.27M1.11%6.38%+29.2%Q3 2025
AURAAura Biosciences, Inc.$3.25M1.10%0.94%Not reportedQ1 2025
WHWKWhitehawk Therapeutics, Inc.$2.76M0.93%2.42%Not reportedQ4 2024
BCABBioAtla, Inc.$2.76M0.93%380.93%Not reportedQ4 2024
QTTBQ32 Bio Inc.$1.64M0.56%3.84%-38.6%Q4 2024
XFORX4 Pharmaceuticals, Inc$1.09M0.37%0.30%Not reportedQ4 2024
ACRVAcrivon Therapeutics, Inc.$977K0.33%1.28%Not reportedQ4 2024
VYNEYarrow Bioscience, Inc.$8270.00%Not reported-99.8%Q4 2024
Q3 2025Reported Nov 17, 202520 positions
CGONCG Oncology, Inc.$45.6M23.14%1.45%Not reportedQ4 2024
URGNUroGen Pharma Ltd.$25.1M12.76%2.69%Not reportedQ4 2024
PBYIPuma Biotechnology, Inc.$21.9M11.14%8.20%Not reportedQ4 2024
TRVITrevi Therapeutics, Inc.$19.6M9.96%1.67%Not reportedQ4 2024
TERNTerns Pharmaceuticals, Inc.$14.8M7.52%2.25%Not reportedQ4 2024
CADLCandel Therapeutics, Inc.$13.2M6.68%4.70%Not reportedQ4 2024
BCAXBicara Therapeutics Inc.$10.2M5.16%1.18%Not reportedQ4 2024
OKUROnKure Therapeutics, Inc.$7.81M3.96%849.31%Not reportedQ4 2024
TARAProtara Therapeutics, Inc.$7.62M3.87%4.54%Not reportedQ4 2024
VSTMVerastem, Inc.$6.88M3.49%1.17%Not reportedQ4 2024
HELPCybin Inc.$4.31M2.19%3.40%Not reportedQ4 2024
CRDFCardiff Oncology, Inc.$4.04M2.05%2.92%+39.3%Q4 2024
AURAAura Biosciences, Inc.$3.68M1.87%0.95%Not reportedQ1 2025
BCABBioAtla, Inc.$3.34M1.69%8.22%Not reportedQ4 2024
JSPRJasper Therapeutics, Inc.$3.29M1.67%4.94%NewQ3 2025
WHWKWhitehawk Therapeutics, Inc.$2.16M1.10%2.42%Not reportedQ4 2024
QTTBQ32 Bio Inc.$1.59M0.81%6.53%Not reportedQ4 2024
XFORX4 Pharmaceuticals, Inc$935K0.47%1.09%+77.8%Q4 2024
ACRVAcrivon Therapeutics, Inc.$733K0.37%1.28%Not reportedQ4 2024
VYNEYarrow Bioscience, Inc.$199K0.10%Not reported-20.4%Q4 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.